Skip to content

Study · Randomized controlled trial · n = 9 · 2017

4 results

Substrate Metabolism and Insulin Sensitivity During Fasting in Obese Human Subjects: Impact of GH Blockade.

Pedersen MH, Svart MV, Lebeck J, Bidlingmaier M, Stødkilde-Jørgensen H, Pedersen SB, Møller N, Jessen N, Jørgensen JOL

The Journal of clinical endocrinology and metabolism1 Apr 2017Cited by 25 (Europe PMC)

PMID28324055 (opens in a new tab)DOI10.1210/jc.2016-3835 (opens in a new tab)PepBankPUB-28324055
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In obese men during fasting, pegvisomant enhanced the reduction in serum IGF-I compared with fasting alone (P < 0.05).

    In plain wordsIn obese men during fasting, pegvisomant reduced serum IGF-I more than fasting alone.

    Peptide
    Pegvisomant
    Outcome
    DecreaseSerum IGF-I reduction
    Study

    n = 9

    Comparator
    72-hour fasting without pegvisomant
    Outcome group
    Growth hormone and IGF-1 · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    the fasting-induced reduction of serum insulin-like growth factor I was enhanced by GHA (P < 0.05).
    2 context sentences
    Summary · context
    Nine obese males were studied thrice in a randomized design: (1) after an overnight fast (control), (2) after 72 hour fasting (fasting), and (3) after 72 hour fasting with GH blockade (pegvisomant) [fasting plus GH antagonist (GHA)].
    Summary · context
    Each study day consisted of a 4-hour basal period followed by a 2-hour hyperinsulinemic, euglycemic clamp combined with indirect calorimetry, assessment of glucose and palmitate turnover, and muscle and fat biopsies.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In obese men during fasting, pegvisomant enhanced suppression of lipid intermediates during the hyperinsulinemic, euglycemic clamp compared with fasting alone.

    In plain wordsIn obese men during fasting, pegvisomant increased clamp-induced suppression of lipid intermediates compared with fasting alone.

    Peptide
    Pegvisomant
    Outcome
    DecreaseLipid intermediate levels during hyperinsulinemic, euglycemic clamp
    Study

    n = 9

    Comparator
    72-hour fasting without pegvisomant
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    but fasting plus GHA caused a more pronounced suppression of lipid intermediates in response to hyperinsulinemic, euglycemic clamp.
    2 context sentences
    Summary · context
    Nine obese males were studied thrice in a randomized design: (1) after an overnight fast (control), (2) after 72 hour fasting (fasting), and (3) after 72 hour fasting with GH blockade (pegvisomant) [fasting plus GH antagonist (GHA)].
    Summary · context
    Each study day consisted of a 4-hour basal period followed by a 2-hour hyperinsulinemic, euglycemic clamp combined with indirect calorimetry, assessment of glucose and palmitate turnover, and muscle and fat biopsies.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In obese men, pegvisomant abolished fasting-induced insulin resistance compared with fasting alone (P < 0.01).

    In plain wordsIn obese men, pegvisomant reversed fasting-induced insulin resistance compared with fasting alone.

    Peptide
    Pegvisomant
    Outcome
    DecreaseInsulin resistance
    Study

    n = 9

    Comparator
    72-hour fasting without pegvisomant
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Fasting-induced insulin resistance was abrogated by GHA (P < 0.01) primarily due to reduced endogenous glucose production (P = 0.003).
    2 context sentences
    Summary · context
    Nine obese males were studied thrice in a randomized design: (1) after an overnight fast (control), (2) after 72 hour fasting (fasting), and (3) after 72 hour fasting with GH blockade (pegvisomant) [fasting plus GH antagonist (GHA)].
    Summary · context
    Each study day consisted of a 4-hour basal period followed by a 2-hour hyperinsulinemic, euglycemic clamp combined with indirect calorimetry, assessment of glucose and palmitate turnover, and muscle and fat biopsies.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In obese men during fasting, pegvisomant reduced endogenous glucose production compared with fasting alone (P = 0.003).

    In plain wordsIn obese men during fasting, pegvisomant reduced the body's glucose production compared with fasting alone.

    Peptide
    Pegvisomant
    Outcome
    DecreaseEndogenous glucose production
    Study

    n = 9

    Comparator
    72-hour fasting without pegvisomant
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Fasting-induced insulin resistance was abrogated by GHA (P < 0.01) primarily due to reduced endogenous glucose production (P = 0.003).
    2 context sentences
    Summary · context
    Nine obese males were studied thrice in a randomized design: (1) after an overnight fast (control), (2) after 72 hour fasting (fasting), and (3) after 72 hour fasting with GH blockade (pegvisomant) [fasting plus GH antagonist (GHA)].
    Summary · context
    Each study day consisted of a 4-hour basal period followed by a 2-hour hyperinsulinemic, euglycemic clamp combined with indirect calorimetry, assessment of glucose and palmitate turnover, and muscle and fat biopsies.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.